The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Lexicon Pharmaceuticals Inc shares valued at $480,000 were purchased by COATS LONNEL on Aug 15 ’24. At $1.60 per share, COATS LONNEL acquired 300,000 shares.
As published in a research note from Leerink Partners on March 05, 2025, Lexicon Pharmaceuticals Inc [LXRX] has been rated down from an Outperform to a Market perform and the price target has been revised to $1 from $2. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in mid June. As of April 30, 2024, Leerink Partners has initiated its “an Outperform” rating for LXRX. Earlier on March 07, 2023, Jefferies initiated its rating. Their recommendation was “a Hold” for LXRX stock.
Analyzing LXRX Stock Performance
During the last five days, there has been a surge of approximately 40.68%. Over the course of the year, Lexicon Pharmaceuticals Inc shares have dropped approximately -4.75%. Shares of the company reached a 52-week high of $1.0900 on 01/24/25 and a 52-week low of $0.2800 on 03/03/25. A 50-day SMA is recorded $0.5070, while a 200-day SMA reached $1.1507.
Support And Resistance Levels for Lexicon Pharmaceuticals Inc (LXRX)
According to the 24-hour chart, there is a support level at 0.6608, which, if violated, would cause prices to drop to 0.6181. In the upper region, resistance lies at 0.7530. The next price resistance is at 0.8025. RSI (Relative Strength Index) is 69.01 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.1298, which suggests the price will decrease in the coming days. Percent R is at 14.13%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
